Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 31
2022 75
2023 76
2024 57
2025 53
2026 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262 results

Results by year

Filters applied: . Clear all
Page 1
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A. Pardanani A. Am J Hematol. 2023 Jul;98(7):1097-1116. doi: 10.1002/ajh.26962. Epub 2023 May 22. Am J Hematol. 2023. PMID: 37309222 Free article.
OVERVIEW: Systemic mastocytosis (SM) results from clonal proliferation of mast cells (MC) in extracutaneous organs. ...
OVERVIEW: Systemic mastocytosis (SM) results from clonal proliferation of mast cells (MC) in extracutaneous organs. ...
Systemic Mastocytosis: State of the Art.
Farmer I, Radia DH. Farmer I, et al. Curr Hematol Malig Rep. 2024 Oct;19(5):197-207. doi: 10.1007/s11899-024-00737-8. Epub 2024 Aug 27. Curr Hematol Malig Rep. 2024. PMID: 39187708 Review.
PURPOSE OF REVIEW: Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), there has been a wealth of new research in therapeutic targeting of the pathogenic C-KIT D816V mutation. ...
PURPOSE OF REVIEW: Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organis …
Systemic mastocytosis: current status and challenges in 2024.
Ustun C, Keklik Karadag F, Linden MA, Valent P, Akin C. Ustun C, et al. Blood Adv. 2025 May 13;9(9):2048-2062. doi: 10.1182/bloodadvances.2024012612. Blood Adv. 2025. PMID: 39853317 Free PMC article. Review.
Systemic mastocytosis (SM) is a rare disease and has had significant discoveries in its biology, prognostication, and management in the past 2 decades. ...
Systemic mastocytosis (SM) is a rare disease and has had significant discoveries in its biology, prognostication, and manageme …
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M. Gotlib J, et al. NEJM Evid. 2023 Jun;2(6):EVIDoa2200339. doi: 10.1056/EVIDoa2200339. Epub 2023 May 23. NEJM Evid. 2023. PMID: 38320129 Clinical Trial.
BACKGROUND: Indolent systemic mastocytosis (ISM) is a clonal mast-cell disease driven by the KIT D816V mutation. ...
BACKGROUND: Indolent systemic mastocytosis (ISM) is a clonal mast-cell disease driven by the KIT D816V mutation. ...
Systemic mastocytosis: 2023 update on diagnosis and management in adults.
Costa A, Scalzulli E, Carmosino I, Capriata M, Ielo C, Masucci C, Passucci M, Martelli M, Breccia M. Costa A, et al. Expert Opin Emerg Drugs. 2023 Dec;28(3):153-165. doi: 10.1080/14728214.2023.2221028. Epub 2023 Jun 6. Expert Opin Emerg Drugs. 2023. PMID: 37256917 Review.
INTRODUCTION: Systemic mastocytosis (SM) is a complex and heterogeneous disease, characterized by the clonal accumulation of mast cells in one or more organs. ...
INTRODUCTION: Systemic mastocytosis (SM) is a complex and heterogeneous disease, characterized by the clonal accumulation of m …
NCCN Guidelines Insights: Systemic Mastocytosis, Version 3.2024.
Gotlib J, Gerds AT, Abdelmessieh P, Ali H, Castells M, Dunbar A, Fein Revell R, George TI, Green S, Gundabolu K, Hexner E, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, Manchanda N, Masarova L, May J, McMahon B, Mohan SR, Nadiminti KV, Oh S, Palmer J, Patel A, Patel AA, Podoltsev N, Rein L, Salit R, Talpaz M, Wadleigh M, Wall S, Bergman MA, Hochstetler C. Gotlib J, et al. J Natl Compr Canc Netw. 2024 Jun;22(2 D):e240030. doi: 10.6004/jnccn.2024.0030. J Natl Compr Canc Netw. 2024. PMID: 38862005
Mastocytosis is a heterogeneous group of disorders comprising cutaneous mastocytosis, systemic mastocytosis, and mast cell sarcoma. It is associated with a variety of symptoms related to the release of mast cell mediators and mast cell tissue infiltration. Re …
Mastocytosis is a heterogeneous group of disorders comprising cutaneous mastocytosis, systemic mastocytosis, and mast c …
The international consensus classification of mastocytosis and related entities.
Leguit RJ, Wang SA, George TI, Tzankov A, Orazi A. Leguit RJ, et al. Virchows Arch. 2023 Jan;482(1):99-112. doi: 10.1007/s00428-022-03423-3. Epub 2022 Oct 10. Virchows Arch. 2023. PMID: 36214901 Review.
This includes indolent forms such as indolent systemic mastocytosis and its subvariant bone marrow mastocytosis, and smoldering systemic mastocytosis as well as aggressive forms including aggressive systemic mastocytosis, systemic …
This includes indolent forms such as indolent systemic mastocytosis and its subvariant bone marrow mastocytosis, and smolderin …
The international consensus classification of eosinophilic disorders and systemic mastocytosis.
Wang SA, Orazi A, Gotlib J, Reiter A, Tzankov A, Hasserjian RP, Arber DA, Tefferi A. Wang SA, et al. Am J Hematol. 2023 Aug;98(8):1286-1306. doi: 10.1002/ajh.26966. Epub 2023 Jun 7. Am J Hematol. 2023. PMID: 37283522 Free article. Review.
Based on new data and increased understanding of disease molecular genetics, the international consensus classification (ICC) has made several changes in the diagnosis and classification of eosinophilic disorders and systemic mastocytosis. Myeloid/lymphoid neoplasms …
Based on new data and increased understanding of disease molecular genetics, the international consensus classification (ICC) has made sever …
New treatments for systemic mastocytosis in 2025.
Costanzo G, Marzio V, Cavaglià E, Paoletti G, Heffler E. Costanzo G, et al. Curr Opin Allergy Clin Immunol. 2025 Aug 1;25(4):277-292. doi: 10.1097/ACI.0000000000001079. Epub 2025 Jun 5. Curr Opin Allergy Clin Immunol. 2025. PMID: 40471046 Review.
PURPOSE OF REVIEW: To provide an accessible, comprehensive overview of past, present, imminent, and future therapies for systemic mastocytosis. RECENT FINDINGS: Based on recent trials, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) have a …
PURPOSE OF REVIEW: To provide an accessible, comprehensive overview of past, present, imminent, and future therapies for systemic …
Hereditary alpha-tryptasemia.
Bonadonna P, Nalin F, Olivieri F. Bonadonna P, et al. Curr Opin Allergy Clin Immunol. 2022 Oct 1;22(5):277-282. doi: 10.1097/ACI.0000000000000849. Epub 2022 Aug 4. Curr Opin Allergy Clin Immunol. 2022. PMID: 35942852 Review.
It is a risk factor for severe anaphylaxis and an established modifier of mast cell mediator-associated symptoms among patients with systemic mastocytosis (SM). SUMMARY: The unique properties of naturally occurring alpha/beta-tryptase heterotetramers may explain cer …
It is a risk factor for severe anaphylaxis and an established modifier of mast cell mediator-associated symptoms among patients with syst …
262 results